Circular Genomics
PrivateLast Round
Series A
Dec 1, 2025
Total Funding Raised
$28.05M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Circular Genomics is a biotechnology company that develops circular RNA-based diagnostic assays and precision medicine tools for psychiatric and neurological conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Mental Health, Drug Discovery
Business Model
B2B
Customer Profile
Usage-Based SaaS, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Circular Genomics Comparables
Compare Circular Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MindX Sciences | 87% | |
| Pax Neuroscience | 79% | |
| ALCEN | 78% |
Circular Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 1, 2025 | ||||
| Grant | Jul 8, 2025 | ||||
| Series A | Jan 24, 2024 | ||||
| Seed | Dec 14, 2021 |
Key People
Founding team and executive leadership
Circular Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UNM Rainforest Innovations | Series A |
| Cottonwood Technology Fund | Series A, Seed |
| Mountain Group Partners | Seed, Series A |
| HIP Fund | Series A |
| Tramway Venture Partners | Series A, Seed |
| Alzheimer's Drug Discovery Foundation | Series A, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 99% MoM, reaching 3K.
- Apr 29, 2026
Co-developing Alzheimer's detection workflow with Vitazi.ai.
Recent news
Latest coverage and updates
- partners_withSep 22, 2026
Circular Genomics Inc. partners with Altoida on an Alzheimer’s multimodal diagnostic collaboration in California and the District of Columbia on Sep 22nd '26
Circular Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Circular Genomics's valuation, stock price, and market status.
Is Circular Genomics a public or private company?
Circular Genomics is a private company.
What is the current stock price of Circular Genomics?
Circular Genomics is a private company, so its shares have no public market price. Caplight tracks Circular Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Circular Genomics worth (valuation)?
Valuation information for Circular Genomics is not publicly available.
Can I buy Circular Genomics stock?
Circular Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Circular Genomics's last funding round?
Circular Genomics's most recent funding round was Series A on December 1, 2025.
Who are the main investors in Circular Genomics?
Key investors in Circular Genomics include Cottonwood Technology Fund, Mountain Group Partners, Tramway Venture Partners.
Will Circular Genomics IPO soon?
No public IPO plans have been announced for Circular Genomics.
How can I track Circular Genomics secondary market activity?
Caplight tracks bids, offers, and trades in Circular Genomics's shares on secondary markets.